Keywords
How to Cite
Abstract
Bringing a new medicine to patients is slow, expensive and uncertain, and about nine in ten candidates that enter human trials never reach approval. This narrative review looks at how artificial intelligence (AI) is being used to attack that problem in three places: choosing drug targets, predicting toxicity before a compound is ever made, and shortening the time between an idea and a clinical trial.
References
Abramson, J., Adler, J., Dunger, J., et al. (2024). Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 630, 493–500.
Jayatunga, M. K. P., Ayers, M., Bruens, L., Jayanth, D., & Meier, C. (2024). How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discovery Today, 29(6), 104009. https://doi.org/10.1016/j.drudis.2024.104009
Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596, 583–589.
Mayr, A., Klambauer, G., Unterthiner, T., & Hochreiter, S. (2016). DeepTox: Toxicity prediction using deep learning. Frontiers in Environmental Science, 3, 80.
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., et al. (2010). How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9, 203–214.
This work is licensed under a Creative Commons Attribution 4.0 International License.
